Related Experiment Video
Updated: Aug 5, 2026

Isolation of Human Islets from Partially Pancreatectomized Patients
Published on: July 30, 2011
Type 3 Autoimmune Pancreatitis: What Do We Know So Far?
Miłosz Caban1, Barbara Włodarczyk2, Łukasz Durko2
1Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Kopcińskiego 22, 90-153, Lodz, Poland. milosz.caban@stud.umed.lodz.pl.
The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs). Type 3 autoimmune pancreatitis (AIP-3) has been proposed as a rare form of pancreatic injury induced by ICIs with autoimmune pancreatitis-like features and variable presentations. Its diagnosis is not straightforward. Moreover, the role of available therapeutic options, particularly mainly glucocorticosteroids (GCS), remains uncertain. Currently, there are no clear guidelines for AIP-3 management. Data on AIP-3 are derived mainly from small retrospective studies and provide limited-quality evidence. In addition, the diagnostic criteria and management of AIP-3 vary substantially between studies. Some researchers have classified asymptomatic pancreatic enzyme elevations during ICI therapy as AIP-3; however, isolated hyperlipasemia should not be considered sufficient for this diagnosis. This comprehensive, narrative review summarizes current knowledge about AIP-3 and discusses epidemiology, etiopathogenesis, clinical presentations, diagnosis, and treatment based on the most recent evidence.
The increasing use of immune checkpoint inhibitors (ICIs) in cancer treatment has led to a rise in immune-related adverse events (irAEs). Type 3 autoimmune pancreatitis (AIP-3) has been proposed as a rare form of pancreatic injury induced by ICIs with autoimmune pancreatitis-like features and variable presentations. Its diagnosis is not straightforward. Moreover, the role of available therapeutic options, particularly mainly glucocorticosteroids (GCS), remains uncertain. Currently, there are no clear guidelines for AIP-3 management. Data on AIP-3 are derived mainly from small retrospective studies and provide limited-quality evidence. In addition, the diagnostic criteria and management of AIP-3 vary substantially between studies. Some researchers have classified asymptomatic pancreatic enzyme elevations during ICI therapy as AIP-3; however, isolated hyperlipasemia should not be considered sufficient for this diagnosis. This comprehensive, narrative review summarizes current knowledge about AIP-3 and discusses epidemiology, etiopathogenesis, clinical presentations, diagnosis, and treatment based on the most recent evidence.
Related Concept Videos
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis II: Pathophysiology
Type I Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Chronic Pancreatitis II: Collaborative Care
Assessment:

